Journal: Respiratory Research

Article Title: CXCL11 levels regulate lung Treg responses to deter the onset of HIV-related COPD

doi: 10.1186/s12931-026-03495-8

Figure Lengend Snippet: The effect of EcoHIV infection and cigarette smoke exposure on lung Cxcl11 expression. A Cxcl11 RT-PCR analysis was conducted on the lungs of EcoHIV infected A/J mice. Data is represented on the y-axis as relative expression compared to PBS treated air-exposed mice. Data is presented as mean ± SEM. ( N ≥ 9 per group). B Cxcl11 RT-PCR was performed on air and smoke exposed control and EcoHIV infected alveolar macrophages from A/J mice. Data is represented on the y-axis as relative expression compared to PBS treated air-exposed mice. Data is presented as mean ± SEM. ( N ≥ 3 per group). C A/J mice were inoculated once with PBS or EcoHIV and exposed to 2 months of room air (RA) or cigarette smoke. Cxcl11 levels in BALF of mice was quantified by ELISA. Data is expressed as mean ± SEM ( N ≥ 3/group)

Article Snippet: D Cxcl11 expression was measured by RT-PCR in mouse alveolar macrophages (ATCC CRL2019) treated with vehicle or 1-mM AZD0530 with or without 5% CSE for 24 h ( N ≥ 6 per group).

Techniques: Infection, Expressing, Reverse Transcription Polymerase Chain Reaction, Control, Enzyme-linked Immunosorbent Assay

Journal: Respiratory Research

Article Title: CXCL11 levels regulate lung Treg responses to deter the onset of HIV-related COPD

doi: 10.1186/s12931-026-03495-8

Figure Lengend Snippet: HuR and c-Src regulate CXCL11 expression in the lung. A CXCL11 mRNA expression was determined via RT-PCR in normal human airway epithelial cells that were treated with 100-ng/ml of actinomycin for a three-hour time period. p < 0.05 comparing the 0 and 1-hour timepoints with the 2 and 3-hour timepoints. B RT-PCR for CXCL11 was conducted as above on human airway epithelial cells treated with control, c-Src or HuR siRNA for 24 h. C Cxcl11 protein levels were measured by ELISA from the BALF of A/J mice treated orally with vehicle or 10 mg/kg AZD0530 while they were exposed to room air or cigarette smoke for one week. Data is presented as mean ± SEM. ( N ≥ 4 per group). D Cxcl11 expression was measured by RT-PCR in mouse alveolar macrophages (ATCC CRL2019) treated with vehicle or 1-mM AZD0530 with or without 5% CSE for 24 h ( N ≥ 6 per group). Data is expressed as relative quantification (RQ) compared to PBS/vehicle treated cells

Article Snippet: D Cxcl11 expression was measured by RT-PCR in mouse alveolar macrophages (ATCC CRL2019) treated with vehicle or 1-mM AZD0530 with or without 5% CSE for 24 h ( N ≥ 6 per group).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Control, Enzyme-linked Immunosorbent Assay, Quantitative Proteomics

Journal: Biosensors

Article Title: Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva

doi: 10.3390/bios13020167

Figure Lengend Snippet: Current-potential profiles ( a , c ) and calibration curves ( b , d ) of neutralizing antibodies sIgA and IgG were obtained using the GLEIA−based electrochemical immunosensor. Current−potential responses were tested under different concentrations of ( a ) sIgA 100 ng/mL (blue), 20 ng/mL (grey), 5 ng/mL (orange), 1 ng/mL (red), and 0 ng/mL (black) and ( c ) IgG 62.5 U/mL (blue), 25 U/mL (grey), 6.25 U/mL (orange), 2.5 U/mL (red), and 0 U/mL (black). Calibration curves were indicated for sIgA ( b ) and IgG ( d ) as Michaelis–Menten-type functions by a non-linear curve fitted in the graphing software Origin2022 (OriginLab).

Article Snippet: As positive controls for neutralizing antibodies, the sIgA antibody (E-AB-V1027, Elabscience, Houston, TX, USA), IgG antibody (SPD-M180, Acro Biosystems, Tokyo, Japan), and IgG standard in the IgG ELISA kit (290-84201, FUJIFILM Wako, Osaka, Japan) were used.

Techniques: Software

Journal: Biosensors

Article Title: Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva

doi: 10.3390/bios13020167

Figure Lengend Snippet: Comparisons of concentrations of neutralizing antibody IgG ( a ) and sIgA ( b ), antioxidant activity (indicated by luminescence inhibition rate) ( c ), and protein concentration ( d ) using saliva samples from 10 individuals are presented together. All 10 saliva samples were collected 3 weeks after the second dose of the vaccine.

Article Snippet: As positive controls for neutralizing antibodies, the sIgA antibody (E-AB-V1027, Elabscience, Houston, TX, USA), IgG antibody (SPD-M180, Acro Biosystems, Tokyo, Japan), and IgG standard in the IgG ELISA kit (290-84201, FUJIFILM Wako, Osaka, Japan) were used.

Techniques: Antioxidant Activity Assay, Inhibition, Protein Concentration

Journal: Biosensors

Article Title: Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva

doi: 10.3390/bios13020167

Figure Lengend Snippet: The four datasets of neutralizing antibodies—IgG and sIgA, antioxidant activity, and protein concentration—measured in 10 samples are depicted individually in a radar chart for each individual. The numbers T1–T10 correspond to the sample numbers 1–10 in . The data are shown as a ratio of the maximum concentration of each measured item.

Article Snippet: As positive controls for neutralizing antibodies, the sIgA antibody (E-AB-V1027, Elabscience, Houston, TX, USA), IgG antibody (SPD-M180, Acro Biosystems, Tokyo, Japan), and IgG standard in the IgG ELISA kit (290-84201, FUJIFILM Wako, Osaka, Japan) were used.

Techniques: Antioxidant Activity Assay, Protein Concentration, Concentration Assay

Journal: Biosensors

Article Title: Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva

doi: 10.3390/bios13020167

Figure Lengend Snippet: The results of continuous monitoring of the concentration of neutralizing IgG ( B ) and sIgA ( C ) antibodies, antioxidant activity ( D ), and protein concentration ( E ) in saliva and neutralizing IgG concentration in serum ( A ) before and after 1st, 2nd, and 3rd vaccinations in the same individual over time were compared vertically. The abscissa represents the date and time of sampling. 0: at first vaccination; 1a: 4 days later, 1b: 1 week later, 1c: 2 weeks later, and 1d: 3 weeks later; 2a: 4 days after second vaccination; 2b: 1 week later, 2c: 2 weeks later, 2d: 3 weeks later, 2e: 1 month later, 2f: 2 months later, 2g: 3 months later, 2h: 4 months later, 2i: 5 months later, 2j: 6 months later, and 2k: 8 months later; 3a: 3 days after the third vaccination, 3b: 2 weeks later, and 3c: 1 month later. The units on the vertical axis are as follows: ( A , B ) U/mL, ( C ) ng/mL, ( D ) %, and ( E ) mg/mL.

Article Snippet: As positive controls for neutralizing antibodies, the sIgA antibody (E-AB-V1027, Elabscience, Houston, TX, USA), IgG antibody (SPD-M180, Acro Biosystems, Tokyo, Japan), and IgG standard in the IgG ELISA kit (290-84201, FUJIFILM Wako, Osaka, Japan) were used.

Techniques: Concentration Assay, Antioxidant Activity Assay, Protein Concentration, Sampling

Journal: Nature communications

Article Title: SuPAR mediates viral response proteinuria by rapidly changing podocyte function.

doi: 10.1038/s41467-023-40165-5

Figure Lengend Snippet: Fig. 4 | Omicron S1 protein distinguished from its 2019-nCov counterpart both biophysically and functionally. a–d S1 protein binding affinity as indicated by surface plasmon resonance assays. As shown, S1 protein was immobilized onto a CM5 sensor chip, while αvβ3 integrin or ACE2 was applied as an analyte in a series of increasing concentrations. Calculation of KD value indicates that 2019-nCov S1 protein bound more tightly to ACE2 (a) and αvβ3 integrin (c), as compared to Omicron S1 protein (b, d). e, f The effects of S1 protein on cultured human podo- cytes. Fully differentiated humanpodocytes were treated for 16 h before harvest for

Article Snippet: To establish the SARS-CoV-2 spike protein inoculation model, 10–12-week-old male C57BL/6j, Plaur−/−, and suPAR-Tg mice (n = 8 in each group) were inoculated intranasally (I/N) with recombinant 2019- nCov spike S1 (Abeomics, 32-190005) at 2.5 ng/g body weight, once a day for 10days.

Techniques: Protein Binding, SPR Assay, Cell Culture

Journal: PeerJ

Article Title: Nationwide wastewater sequencing surveillance of SARS-CoV-2 lineages: validation against clinical data across 28 U.S. states

doi: 10.7717/peerj.20941

Figure Lengend Snippet: Spearman rank correlation coefficient between wastewater abundances and clinical abundances of SARS-CoV-2 lineages. All correlations were positive and significant after a Bonferroni correction, indicating clear agreement. Lower correlation coefficients are thought to be a result of either limited data points (BA) or ongoing epidemiological dynamics (LF, KP) for more recent lineages.

Article Snippet: For all sequencing runs, SARS-CoV-2 gRNA (ATCC VR-1986D), an early isolate of the original SARS-CoV-2 virus from March of 2020 in Washington, is used as a positive control (GenBank: MT246667.1 ).

Techniques:

Journal: PeerJ

Article Title: Nationwide wastewater sequencing surveillance of SARS-CoV-2 lineages: validation against clinical data across 28 U.S. states

doi: 10.7717/peerj.20941

Figure Lengend Snippet: Box and whisker plot of days from average emergence (defined as the date in which a lineage represented over 10% of the total abundance of lineages in at least 5 of our sites) for each SARS-CoV-2 lineage lineage. Each dot represents an individual WWTP. A larger spread indicates a slower spread across the country. Negative values represent an earlier emergence. Each of these dates is calculated with respect to each lineage’s average emergence across all sites.

Article Snippet: For all sequencing runs, SARS-CoV-2 gRNA (ATCC VR-1986D), an early isolate of the original SARS-CoV-2 virus from March of 2020 in Washington, is used as a positive control (GenBank: MT246667.1 ).

Techniques: Whisker Assay